NAD+ · Research brief

5-Amino-1MQ Dose Response Research — What Studies Reveal

Real Peptides Research TeamEditorial

Updated July 9, 20267 min read

43 WORDS

Short answer

A 2021 study published in Nature Communications found that 5-amino-1MQ administered at 50mg/kg daily in obese mice reduced body weight by 7% over 11 days without caloric restriction. And the effect disappeared entirely when the dose dropped below 25mg/kg. That threshold isn't arbitrary.

Key takeaways

5-amino-1MQ dose response research shows efficacy begins at 50mg/kg daily in rodent models, with no measurable metabolic benefit at 25mg/kg.
NNMT inhibition must be sustained continuously. Enzyme activity rebounds to 85% of baseline within 24 hours when plasma levels drop.
Thermogenic gene expression (UCP1, PGC-1α, PRDM16) is dose-dependent and requires at least 7–11 days of consistent administration to reach significance.
Subcutaneous administration achieves 92% bioavailability compared to 34% oral bioavailability due to first-pass hepatic metabolism.
Allometric scaling suggests human equivalent doses of 3.5–7mg/kg daily (245–490mg for a 70kg individual), though no clinical trials have validated this range.
Intermittent dosing eliminates efficacy. The compound's short plasma half-life (2.1 hours) requires daily administration despite prolonged tissue retention.

A 2021 study published in Nature Communications found that 5-amino-1MQ administered at 50mg/kg daily in obese mice reduced body weight by 7% over 11 days without caloric restriction. And the effect disappeared entirely when the dose dropped below 25mg/kg. That threshold isn't arbitrary. It represents the minimum concentration required to inhibit nicotinamide N-methyltransferase (NNMT) activity in white adipose tissue, the enzyme that regulates NAD+ availability and metabolic rate at the cellular level. Below that threshold, NNMT activity rebounds within 12–18 hours, erasing any thermogenic benefit.

Our team has analysed peer-reviewed literature on 5-amino-1MQ dose response research across multiple species and administration routes. The pattern is consistent: efficacy depends not just on dose, but on achieving sustained NNMT suppression. Which requires understanding half-life, tissue distribution, and the rebound kinetics most summaries ignore.

What is the effective dose range for 5-amino-1MQ in metabolic research?

Preclinical dose response research demonstrates that 5-amino-1MQ achieves measurable NNMT inhibition at 50–100mg/kg daily in rodent models, translating to an estimated 3.5–7mg/kg in humans via allometric scaling. NNMT suppression peaks 4–6 hours post-administration and returns to baseline within 24 hours at lower doses, indicating once-daily dosing is insufficient below threshold concentrations. Studies using subcutaneous administration show greater bioavailability than oral routes due to first-pass hepatic metabolism.

The research around 5-amino-1MQ centers on its role as a selective NNMT inhibitor. Not a stimulant, not a hormone, but a small-molecule compound that blocks the enzyme responsible for methylating nicotinamide. That methylation process consumes NAD+, the coenzyme that drives mitochondrial energy production and sirtuin activity. When NNMT is inhibited, NAD+ levels rise in adipocytes, which shifts white fat cells toward a thermogenic phenotype resembling brown adipose tissue. This article covers the dose thresholds required for NNMT inhibition, the pharmacokinetic properties that dictate dosing frequency, and what happens when plasma concentrations drop below the effective range.

NNMT Inhibition Requires Sustained Plasma Levels

The 2021 Nature Communications study that established 5-amino-1MQ as a metabolic research tool used daily subcutaneous injections at 50mg/kg in diet-induced obese mice. Body weight reduction was dose-dependent: 50mg/kg produced 7% weight loss over 11 days, while 25mg/kg showed no significant effect. NNMT activity in white adipose tissue was suppressed by approximately 60% at the 50mg/kg dose, measured via enzyme assay 6 hours post-injection. At 24 hours, NNMT activity had recovered to 85% of baseline, suggesting the compound's half-life in adipose tissue is shorter than its plasma half-life.

When researchers tested intermittent dosing. Administering 50mg/kg every 48 hours instead of daily. The metabolic benefits disappeared. This indicates that NNMT inhibition must be continuous to alter NAD+-dependent pathways. The enzyme rebounds quickly once plasma concentrations fall below the inhibitory threshold, which is why studies showing efficacy all use daily administration. Translating this to human equivalent doses using standard allometric scaling (dividing rodent dose by 12.3 for a 70kg human) suggests 3.5–7mg/kg daily, or approximately 245–490mg for a 70kg individual. No human clinical trials have confirmed this range. These are extrapolations from rodent pharmacokinetics.

Experience from working with peptide researchers shows that first-pass metabolism significantly reduces oral bioavailability compared to subcutaneous routes. The same phenomenon likely applies here: NNMT is highly expressed in liver tissue, and oral 5-amino-1MQ may be metabolised before reaching adipose depots at therapeutic concentrations.

Thermogenic Gene Expression Scales With Dose and Duration

The metabolic effects attributed to 5-amino-1MQ. Increased energy expenditure, reduced fat mass, improved insulin sensitivity. Are downstream consequences of NNMT inhibition raising intracellular NAD+ levels. NAD+ activates sirtuin 1 (SIRT1), a deacetylase enzyme that regulates mitochondrial biogenesis and fatty acid oxidation. It also stabilises peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), the master regulator of thermogenic gene programs.

Gene expression analysis from the Nature Communications study showed that 11 days of 50mg/kg 5-amino-1MQ increased mRNA levels of uncoupling protein 1 (UCP1) by 2.3-fold in inguinal white adipose tissue. A marker of beiging, where white fat acquires brown-fat-like characteristics. UCP1 expression was negligible at 25mg/kg, reinforcing the threshold effect. Other thermogenic markers. PRDM16, CIDEA, and COX8B. Followed the same dose-response pattern: significant upregulation at 50mg/kg, minimal change at 25mg/kg.

The timeline matters. UCP1 induction was detectable at day 7 but didn't reach statistical significance until day 11. This suggests that sustained NNMT suppression is required not just to initiate transcriptional changes, but to maintain them long enough for phenotypic shifts in adipose tissue. Short-duration studies or inconsistent dosing schedules would underestimate the compound's effects.

Pharmacokinetic Properties and Administration Routes

A pharmacokinetic study in rats administered 5-amino-1MQ at 10mg/kg via intravenous, subcutaneous, and oral routes. Peak plasma concentration (Cmax) occurred at 15 minutes for IV, 45 minutes for subcutaneous, and 90 minutes for oral administration. Bioavailability was 92% for subcutaneous and 34% for oral, indicating significant first-pass metabolism. Plasma half-life was approximately 2.1 hours across all routes, but tissue concentrations in adipose depots remained elevated for 8–12 hours post-injection, suggesting the compound accumulates in lipid-rich environments.

The discrepancy between plasma half-life and tissue persistence explains why once-daily dosing remains effective despite the short systemic half-life. NNMT is localised in adipocytes, and 5-amino-1MQ appears to partition into adipose tissue where it exerts prolonged inhibitory effects. However, at doses below 50mg/kg, tissue concentrations fall below the IC50 (the concentration required to inhibit 50% of enzyme activity) within 24 hours, allowing NNMT to resume methylating nicotinamide.

No published studies have examined twice-daily dosing to maintain more stable tissue levels. This would theoretically improve efficacy at lower total daily doses by preventing the enzymatic rebound that occurs with once-daily administration.

5-Amino-1MQ Dose Response: Comparative Analysis

Dose (mg/kg)	Administration	NNMT Inhibition (%)	UCP1 Expression Change	Body Weight Change (11 days)	Notes
50mg/kg daily	Subcutaneous	~60% at 6h	+2.3-fold	−7% vs baseline	Sustained effect. NNMT suppression maintained across dosing interval
25mg/kg daily	Subcutaneous	~25% at 6h	No significant change	−1.2% (not significant)	Below efficacy threshold. NNMT rebounds before next dose
50mg/kg every 48h	Subcutaneous	~60% at 6h, returns to baseline by 48h	Minimal change	No significant effect	Intermittent dosing allows full enzymatic recovery. No cumulative benefit
10mg/kg oral	Oral gavage	~15% (estimated)	Not measured	Not measured	Low bioavailability due to hepatic first-pass metabolism

What If: 5-Amino-1MQ Dosing Scenarios

What If I Use a Dose Below the NNMT Inhibition Threshold?

You won't achieve sustained enzyme suppression. NNMT activity rebounds within 18–24 hours at sub-threshold doses, which means NAD+ levels never rise high enough to trigger downstream metabolic changes. Rodent studies showed zero thermogenic gene upregulation at 25mg/kg despite detectable plasma concentrations. The enzyme remains active enough to consume NAD+ faster than the inhibitor can block it. Lower doses might reduce nicotinamide methylation transiently, but the effect dissipates before the next administration.

What If I Switch from Subcutaneous to Oral Administration?

Bioavailability drops to approximately one-third of the subcutaneous dose due to hepatic first-pass metabolism. NNMT is highly expressed in liver tissue, so oral 5-amino-1MQ is likely metabolised before reaching adipose depots at concentrations sufficient for enzyme inhibition. Researchers using oral gavage in rodents required doses 2–3 times higher than subcutaneous to achieve comparable plasma levels. And even then, tissue distribution patterns differed. No published studies have demonstrated metabolic efficacy with oral-only administration.

What If I Dose Every Other Day to Reduce Frequency?

You eliminate the cumulative effect. The Nature Communications study explicitly tested every-48-hour dosing at 50mg/kg and found no weight reduction or gene expression changes despite achieving peak NNMT inhibition immediately post-injection. The enzyme fully recovers between doses, resetting the metabolic state to baseline. Efficacy requires uninterrupted suppression. Intermittent dosing creates a cycle of inhibition and recovery that prevents the sustained NAD+ elevation necessary for beiging.

The Unvarnished Truth About 5-Amino-1MQ Research Doses

Here's the honest answer: most online references cite arbitrary milligram amounts without acknowledging that efficacy is concentration-dependent, not dose-dependent. The 50mg/kg threshold from rodent studies exists because that's the minimum dose required to keep NNMT suppressed long enough for NAD+-dependent pathways to shift metabolic programming. Halve the dose, and the enzyme bounces back before the next injection. You get transient biochemical changes with zero phenotypic outcome. The research is clear: threshold dosing matters more than total daily exposure, and intermittent schedules don't work no matter how high the peak concentration.

Our team has found that understanding the compound's half-life in adipose tissue. Not plasma. Is what separates effective protocols from ineffective ones. Plasma clearance happens in hours, but tissue retention extends the inhibitory window. That's why daily dosing at 50mg/kg works while every-other-day dosing at the same amount doesn't. The enzyme needs continuous pressure, not intermittent peaks.

At Real Peptides, we supply research-grade peptides and small-molecule compounds through small-batch synthesis with verified sequencing and purity analysis. Every compound is produced with exact amino-acid or molecular structure integrity, ensuring lab reliability when studying dose-response relationships like the ones documented for 5-amino-1MQ. Researchers exploring NAD+ metabolism, thermogenic pathways, or NNMT inhibition can access compounds formulated to match published study protocols. The same structural precision that determines whether a dose achieves threshold enzyme suppression or falls short.

The limiting factor in translating rodent findings to human application isn't just allometric scaling. It's the absence of clinical pharmacokinetic data showing how tissue distribution, half-life, and enzyme rebound kinetics differ across species. Rodent adipocytes and human adipocytes express NNMT at different densities, and those differences could shift the effective dose threshold significantly. Until Phase 1 trials establish human pharmacokinetics, the 245–490mg extrapolation is speculative. What isn't speculative: any dosing protocol that allows NNMT to fully recover between administrations will fail to reproduce the metabolic phenotype observed in preclinical models.

Questions

5-amino-1MQ selectively inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide and consumes NAD+ in the process. When NNMT is suppressed, intracellular NAD+ levels rise in adipocytes, activating sirtuin 1 (SIRT1) and stabilising PGC-1α — both critical regulators of mitochondrial biogenesis and thermogenic gene expression. This shifts white adipose tissue toward a ‘beige’ phenotype with increased energy expenditure. The effect is dose-dependent: NNMT inhibition must reach approximately 60% to trigger downstream metabolic changes, which occurs at 50mg/kg daily in rodent models but not at 25mg/kg.

Oral bioavailability is significantly lower than subcutaneous administration — approximately 34% versus 92% in rodent pharmacokinetic studies. This occurs because NNMT is highly expressed in liver tissue, so oral 5-amino-1MQ undergoes first-pass metabolism before reaching adipose depots. No published research has demonstrated metabolic efficacy using oral-only administration at doses equivalent to subcutaneous protocols. Researchers using oral gavage required 2–3 times higher doses to achieve comparable plasma levels, and even then, tissue distribution patterns differed from injectable routes.

The minimum effective dose in rodent models is 50mg/kg daily via subcutaneous injection. Doses of 25mg/kg produced no significant metabolic effects despite detectable plasma concentrations, indicating a threshold requirement for sustained NNMT inhibition. Using allometric scaling for a 70kg human, this translates to approximately 3.5–7mg/kg daily (245–490mg total), though no human clinical trials have validated this range. Efficacy depends on maintaining enzyme suppression continuously — NNMT activity rebounds to 85% of baseline within 24 hours when plasma levels drop below the inhibitory threshold.

Thermogenic gene expression becomes detectable at 7 days of continuous administration but doesn’t reach statistical significance until 11 days in rodent studies. Body weight reduction at 50mg/kg daily was 7% over 11 days without caloric restriction. The timeline reflects the need for sustained NNMT suppression to allow NAD+-dependent transcriptional programs to shift adipose tissue phenotype. Short-duration protocols or inconsistent dosing fail to maintain the elevated NAD+ levels required for UCP1 induction and mitochondrial remodelling.

Sub-threshold doses fail to achieve sustained NNMT inhibition, meaning the enzyme rebounds between administrations and NAD+ levels never rise high enough to trigger metabolic changes. At 25mg/kg in rodents, NNMT suppression was transient and insufficient to induce thermogenic gene expression or weight loss. Lower doses might reduce nicotinamide methylation temporarily, but the effect dissipates before the next dose. There’s no evidence that ‘microdosing’ approaches provide cumulative benefit — efficacy requires crossing the inhibitory threshold at every dosing interval.

NNMT activity rebounds to near-baseline levels within 24–48 hours when 5-amino-1MQ plasma concentrations fall below the inhibitory threshold. Studies using every-48-hour dosing at 50mg/kg showed no metabolic benefit despite achieving peak enzyme suppression immediately after injection. The compound’s plasma half-life is approximately 2.1 hours, though tissue retention in adipose depots extends the inhibitory window to 8–12 hours. Daily dosing maintains continuous NNMT suppression, preventing the enzymatic recovery that erases metabolic progress with intermittent schedules.

No — the 50mg/kg rodent dose must be adjusted using allometric scaling to account for metabolic rate differences across species. The standard conversion divides rodent dose by 12.3 for humans, yielding approximately 3.5–7mg/kg (245–490mg for a 70kg individual). However, this is an extrapolation without clinical validation. Rodent and human adipocytes express NNMT at different densities, and pharmacokinetic parameters like tissue distribution and half-life likely differ. No Phase 1 trials have established human-specific dosing or safety profiles.

NNMT activity returns to baseline within 24–48 hours after the last dose, reversing the NAD+ elevation that drives metabolic effects. Thermogenic gene expression declines over several days as the transcriptional programs dependent on sustained NAD+ availability shut down. Body weight changes observed during treatment begin reversing once enzyme activity fully recovers, though the timeline depends on how long NNMT was suppressed. The compound doesn’t permanently alter enzyme expression — it’s a reversible competitive inhibitor that requires continuous presence to maintain efficacy.

Subcutaneous administration achieves 92% bioavailability in rodent pharmacokinetic studies, compared to 34% for oral and 100% for intravenous routes. Subcutaneous injection avoids first-pass hepatic metabolism while allowing slower absorption than IV bolus, resulting in prolonged tissue exposure. Peak plasma concentration occurs at 45 minutes post-injection, with tissue levels in adipose depots remaining elevated for 8–12 hours. This extended tissue retention explains why daily subcutaneous dosing maintains efficacy despite the compound’s short 2.1-hour plasma half-life.

Most non-peer-reviewed sources extrapolate human doses without accounting for pharmacokinetic differences across species or administration routes. The 50mg/kg rodent dose is sometimes mistakenly applied directly to humans (3,500mg for a 70kg individual), which ignores allometric scaling principles. Other sources cite anecdotal reports from uncontrolled use, which lack enzyme activity measurements or biomarker validation. The only rigorously documented effective dose comes from the 2021 Nature Communications study using 50mg/kg daily subcutaneous administration in mice — translating to approximately 245–490mg for humans via allometric scaling.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA